News covered here includes decent results from an elderly industrial group, weighed down by a substantial legacy pension issue. Despite plenty of demands on its cash, the valuation looks pretty appealing, as you can discover in our assessment here. Elsewhere, patient shareholders in a UK chocolate maker will be revelling in a bid at a big premium.
Verici: shares soar on agreement Shares in Verici Dx (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, rose 71% on news of a significant new agreement. Verici has signed an exclusive global licensing agreement with US-listed Thermo Fisher Scientific (US:TMO), a US$177 billion business, the world leader in serving science, to further develop an assay for pre-transplant prognostic testing for risk of early kidney rejection. The exclusive license grants Thermo Fisher the rights to develop an assay for pre-transplant risk assessment for further development as a Laboratory Developed Test ("LDT") in its CLIA laboratory in the U.S.,…
Sign up and read the full article
Register to continue reading our content.
Get FREE access now
Already a member? Login